Skip to main content
Clinical Trials/EUCTR2014-000914-76-IT
EUCTR2014-000914-76-IT
Active, not recruiting
Phase 1

A Multicenter, Double-blind, Randomized, Clinical Study to Assess the Efficacy and Safety of Intravenous S-649266 in Complicated Urinary Tract Infections with or without Pyelonephritis or Acute Uncomplicated Pyelonephritis Caused by Gram-Negative Pathogens in Hospitalized Adults in Comparison with Intravenous Imipenem/Cilastatin

Shionogi Inc.0 sites300 target enrollmentAugust 26, 2014
DrugsZienam

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Shionogi Inc.
Enrollment
300
Status
Active, not recruiting
Last Updated
9 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 26, 2014
End Date
TBD
Last Updated
9 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Hospitalized patients who have a clinical diagnosis of either cUTI with or without pyelonephritis or acute uncomplicated pyelonephritis, and who have provided written informed consent or informed consent provided by legal guardian. (Note: Country specific rules and local Ethics Committee approval for legal guardian informed consent will determine whether or not a patient unable to comprehend or sign the informed consent is allowed to be enrolled in the study).
  • The specific clinical diagnosis will include:
  • cUTI with a history of at least one of the following:
  • Indwelling urinary catheter
  • Urinary retention (at least 100 mL of residual urine after voiding)
  • Neurogenic bladder
  • Obstructive uropathy
  • Azotemia (BUN and creatinine values greater than normal laboratory values)
  • Pyelonephritis and normal urinary tract anatomy, ie, acute uncomplicated pyelonephritis
  • All patients must have at least two of the following signs or symptoms:

Exclusion Criteria

  • 1\. Have a history of hypersensitivity reactions to carbapenems, cephalosporins, penicillins, or other ß\-lactam antibiotics
  • 2\. Patient's urine culture at study entry isolates more than 2 microorganisms, regardless of colony count, or patient has a confirmed fungal UTI.
  • 3\. Patients with asymptomatic bacteriuria, the presence of \=100000CFU/mL of a uropathogen and pyuria but without local or systemic symptoms
  • 4\. Patient is receiving hemodialysis or peritoneal dialysis. Impairment of renal function with an estimated CrCl \= 20 mL/min, requirement for peritoneal dialysis, hemodialysis or hemofiltration, or oliguria (\< 20 mL/h urine output over 24 hours).

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
A randomized study in hospitalised patients with complicated urinary tract infections caused by Gram-negative bacteria to compare the efficacy and safety of S-649266 to Imipenem/Cilastin, both administered by intravenous infusio
EUCTR2014-000914-76-LVShionogi Inc.400
Active, not recruiting
Phase 1
A randomized study in hospitalised patients with complicated urinary tract infections caused by Gram-negative bacteria to compare the efficacy and safety of S-649266 to Imipenem/Cilastin, both administered by intravenous infusioComplicated Urinary Tract Infections with or without Pyelonephritis or Acute Uncomplicated Pyelonephritis caused by Gram-negative PathogensMedDRA version: 19.0Level: HLTClassification code 10046577Term: Urinary tract infectionsSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
EUCTR2014-000914-76-CZShionogi Inc.450
Active, not recruiting
Phase 1
A randomized study in hospitalised patients with complicated urinary tract infections caused by Gram-negative bacteria to compare the efficacy and safety of S-649266 to Imipenem/Cilastin, both administered by intravenous infusioComplicated Urinary Tract Infections with or without Pyelonephritis or Acute Uncomplicated Pyelonephritis caused by Gram-negative PathogensMedDRA version: 19.0Level: HLTClassification code 10046577Term: Urinary tract infectionsSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
EUCTR2014-000914-76-DEShionogi Inc.450
Active, not recruiting
Phase 1
A randomized study in hospitalised patients with complicated urinary tract infections caused by Gram-negative bacteria to compare the efficacy and safety of S-649266 to Imipenem/Cilastin, both administered by intravenous infusio
EUCTR2014-000914-76-HUShionogi Inc.450
Active, not recruiting
Phase 1
A randomized study in hospitalised patients with complicated urinary tract infections caused by Gram-negative bacteria to compare the efficacy and safety of S-649266 to Imipenem/Cilastin, both administered by intravenous infusioComplicated Urinary Tract Infections with or without Pyelonephritis or Acute Uncomplicated Pyelonephritis caused by Gram-negative PathogensMedDRA version: 17.1Level: HLTClassification code 10046577Term: Urinary tract infectionsSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
EUCTR2014-000914-76-ROShionogi Inc.300